Blood Pressure Medication Recalled Due to Cancer-Causing Chemicals
Teva Pharmaceuticals has initiated a recall of over 580,000 bottles of Prazosin Hydrochloride, a blood pressure medication. This decision follows FDA tests revealing elevated levels of potentially cancer-causing chemicals.
Details of the Recall
The recall was officially announced on October 7, due to the discovery of excess amounts of the impurity N-nitroso Prazosin impurity C in the capsules. These capsules, available in 1, 2, and 5 mg dosages, have been distributed nationwide.
FDA Classification
- The FDA has classified this recall as Class II.
- This classification indicates a risk of short-term or reversible health effects.
- Serious long-term harm is considered unlikely.
Risk Assessment
The Health Hazard Assessment conducted by Teva USA rated the overall risk to patients as medium. However, as of the latest updates, the company has not reported any relevant complaints associated with the affected product.
About Prazosin
Prazosin, commonly known by its brand name Minipress, is classified as an alpha-blocker. It is commonly prescribed to manage hypertension and lower blood pressure. Patients concerned about their prescriptions are urged to consult their pharmacy or healthcare provider.
Patient Safety Measures
Teva Pharmaceuticals emphasizes its commitment to patient safety and product quality. The company has distributed recall letters with detailed instructions on how to return the affected medication. A complete list of the specific lots that are recalled can be accessed for reference.
Patients are encouraged to stay informed and take necessary precautions to ensure their health and safety.
